Author:
Scott Lesley J.,Keam Susan J.
Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. Liebow A, Li X, Racie T, et al. An investigational RNAi therapeutic targeting glycolate oxidase reduces oxalate production in models of primary hyperoxaluria. J Am Soc Nephrol. 2017;28(2):494–503.
2. Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med. 2013;369(7):649–58.
3. Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19(10):673–94.
4. Debacker AJ, Voutila J, Catley M, et al. Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug. Mol Ther. 2020;28(8):1759–71.
5. European Commission. Commission implementing decision of 19.11.20 granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for "Oxlumo—lumasiran, an orphan medicinal product for human use. 2020. http://ec.europa.eu/health/documents/community-register/html/h1496.htm. Accessed 24 Nov 2020.
Cited by
191 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献